Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma.
Kevin Charles MillerAshish V ChintakuntlawarCrystal HilgerIrina BancosJohn C MorrisMabel RyderCarin Y SmithSarah M JenkinsKeith C BiblePublished in: Journal of the Endocrine Society (2020)
Our single-institution experience suggests that select ACC patients respond to late-line MKI or checkpoint inhibition despite resistance to cytotoxic agents. These treatments may be attractive to ACC patients with limited other therapeutic options. The use of MKI and immunotherapy in ACC warrants prospective investigation emphasizing parallel correlative studies to identify biomarkers that predict for response.